The Cognitive Neuroscience Unit (CNU) has been conceived and designed based on the premise that cognitive neuroscience methods are now central to interventions research in schizophrenia. The Principal Investigator argues persuasively that because neurocognitive deficits are a core feature of schizophrenia and are important predictors of outcome, neurocognitive deficits represent a critical intervention target. Cognitive neuroscience methods provide measures of brain structure and function that can significantly augment standard symptomatology ratings. Thus, neurocognitive indices offer the potential to classify more specific intervention-relevant patient subgroups, identify the stable enduring features of the illness that are most likely to predict distinctive outcomes, and identify individuals who are at increased risk for schizophrenia and may benefit from early intervention strategies. The proposed CNU is designed to provide an infrastructure ensuring uniform, state of the art neurocognitive methodology across all intervention studies. The CNU has 3 main scientific goals: 1) To specific cognitive targets for interventions and measure the effects of interventions, 2) To develop and implement new neurocognitive methods with greater sensitivity to pharmacologic outcomes, and 3) To identify neurocognitive indices with potential to predict morbidity in high risk samples, differential treatment response and outcome, and longitudinal course characteristics. The 3 service goals of the CNU are to provide: 1) uniform data acquisition and analysis methods across studies by providing a core neurocognitive battery, standardized procedures for structural and functional neuroimaging, electrophysiological (EP) recording, and analysis, and 3) a unique education and training environment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
1P30MH060575-01
Application #
6315894
Study Section
Special Emphasis Panel (ZMH1-CRB-H (02))
Project Start
2000-02-18
Project End
2005-01-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
$175,212
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
DeRosse, Pamela; Nitzburg, George C; Kompancaril, Bernie et al. (2014) The relation between childhood maltreatment and psychosis in patients with schizophrenia and non-psychiatric controls. Schizophr Res 155:66-71
Wellington, Robin L; Bilder, Robert M; Napolitano, Barbara et al. (2013) Effects of age on prefrontal subregions and hippocampal volumes in young and middle-aged healthy humans. Hum Brain Mapp 34:2129-40
Kane, John M; Kishimoto, Taishiro; Correll, Christoph U (2013) Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 66:S37-41
Ardekani, Babak A; Tabesh, Ali; Sevy, Serge et al. (2011) Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. Hum Brain Mapp 32:1-9
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Lencz, Todd; Robinson, Delbert G; Napolitano, Barbara et al. (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20:569-72
Coscia, Denise M; Narr, Katherine L; Robinson, Delbert G et al. (2009) Volumetric and shape analysis of the thalamus in first-episode schizophrenia. Hum Brain Mapp 30:1236-45
Lencz, Todd; Lipsky, Robert H; DeRosse, Pamela et al. (2009) Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 194:313-8
Szeszko, Philip R; Hodgkinson, Colin A; Robinson, Delbert G et al. (2008) DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 79:103-10
Szeszko, Philip R; Robinson, Delbert G; Ashtari, Manzar et al. (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 33:976-84

Showing the most recent 10 out of 44 publications